XML 37 R21.htm IDEA: XBRL DOCUMENT
v3.20.2

Product Sales (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Revenues [Abstract] |
Schedule of product sales | Net product sales consist of the following:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
Net Product Sales in the United States |  | 2020 |  | 2019 |  | 2020 |  | 2019
EYLEA® |  | $ | 1,318.3 |  |  | $ | 1,187.7 |  |  | $ | 3,604.0 |  |  | $ | 3,422.1 |
Libtayo® |  | 71.6 |  |  | 47.6 |  |  | 196.6 |  |  | 115.2 |
Praluent® |  | 48.5 |  |  | * |  | 95.7 | * |  | *
REGN-COV2 |  | 40.2 |  |  | — |  |  | 40.2 |  |  | — |
ARCALYST® |  | 3.6 |  |  | 3.0 |  |  | 9.3 |  |  | 10.7 |
|  | $ | 1,482.2 |  |  | $ | 1,238.3 |  |  | $ | 3,945.8 |  |  | $ | 3,548.0 |
* Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.
Schedules of Concentration of Risk, by Risk Factor | Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2020 |  | 2019 |  | 2020 |  | 2019
Besse Medical, a subsidiary of AmerisourceBergen Corporation |  | 50 | % |  | 57 | % |  | 52 | % |  | 57 | %
McKesson Corporation |  | 34 | % |  | 34 | % |  | 34 | % |  | 33 | %

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration